Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
-
Clinical Benefit
Substantial
The actual benefit of XELODA is substantial.
Clinical Added Value
no clinical added value
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator.
Listen
